USPTO Art Unit 1632 Prosecution Statistics

Art Unit Information

Art Unit: 1632
Group: 1630
Tech Center: 1600
Total Cases: 11,316
Last Active: October 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19355669MUSCLE-SPECIFIC EXPRESSION CASSETTESOctober 2025March 2026Allow500NoNo
19228566SYSTEMS AND METHODS FOR REVERSIBLE CRYOPRESERVATIONJune 2025January 2026Allow710YesNo
19227561BRAIN ORGANOID CONTAINING OPTIC VESICLES GENERATED BASED ON H9 INDUCTION AND EYE-BRAIN FUSION CULTURE METHODJune 2025February 2026Allow811YesNo
19181736METHOD FOR CULTURING PRIMARY CANCER CELLS THROUGH SIMULATED MICROGRAVITY-INDUCED REPROGRAMMING AND APPLICATIONS THEREOFApril 2025December 2025Allow811NoNo
19093919METHODS FOR PREPARING MESENCHYMAL STEM CELLSMarch 2025January 2026Abandon910NoNo
19029060CULTURE MEDIA BASED ON PROTEIN HYDROLYSATE AND A PROCESS FOR PREPARING THEREOFJanuary 2025January 2026Allow1220YesNo
19025996METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLSJanuary 2025October 2025Allow930YesNo
18992213OPTIMIZED METHOD FOR EXPANSION AND LARGE-SCALE PRODUCTION OF REGULATORY T CELLS (Tregs)January 2025February 2026Allow1320YesNo
18999456TARGETING THE PVR AXIS USING CAR T CELL THERAPY AND COMBINATIONSDecember 2024June 2025Allow510NoNo
18984398METHOD FOR GENERATING GENOME-EDITED CHICKENSDecember 2024June 2025Allow610YesNo
18948566GENETICALLY MODIFIED RAT HAVING PKHD1L1 GENE WITH POINT MUTATION AND METHODS FOR ITS CONSTRUCTION, DETECTION AND USENovember 2024February 2026Allow1521YesNo
18929934COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSOctober 2024July 2025Allow920NoNo
18930053COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSOctober 2024July 2025Allow920NoNo
18904578ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATIONOctober 2024February 2025Allow410YesNo
18902255TRANSGENIC ANGELFISHSeptember 2024July 2025Allow921YesNo
18807211RECOMBINANT ADENO-ASSOCIATED VIRUS WITH MODIFIED AAV CAPSID POLYPEPTIDESAugust 2024August 2025Allow1221NoNo
18768392Compositions Derived from Placenta and Methods of Producing the SameJuly 2024January 2026Allow1931YesNo
18760465MOUSE HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENEJuly 2024October 2025Allow1511YesNo
18758838METHODS AND MODELS FOR ASSESSING EFFICACY OF IMMUNOTHERAPIESJune 2024May 2025Allow1120YesNo
18744550COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM CELL TRANSPLANTSJune 2024September 2025Allow1501NoNo
18742917METHODS FOR DIFFERENTIATING DOPAMINERGIC NEURONS FROM STEM CELLSJune 2024November 2025Allow1731NoNo
18735079METHOD FOR ANALYZING CONTENT AND DISTRIBUTION OF MICROPLASTICS IN MARINE CNIDARIA ORGANISMSJune 2024January 2025Allow710NoNo
18670347Formation of Three-Dimensional Organ from Pluripotent Stem CellsMay 2024March 2026Allow2141NoNo
18668092METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTSMay 2024December 2025Allow1950YesNo
18662902ENDOCRINE CELLS THAT EXPRESS CHROMOGRANIN AMay 2024August 2025Abandon1521NoNo
18662102MODULAR GENETICALLY ENGINEERED CELL AND METHODS OF GENERATION THEREOFMay 2024August 2025Allow1511YesNo
18660825TRANSGENIC CORYMay 2024May 2025Abandon1321YesNo
18658343UNIVERSAL DONOR STEM CELLS AND RELATED METHODSMay 2024August 2025Allow1511YesNo
18658385UNIVERSAL DONOR STEM CELLS AND RELATED METHODSMay 2024February 2026Allow2121YesNo
18650881ENGINEERED IMMUNE CELLS WITH RECEPTOR SIGNAL STRENGTH MODULATED BY A HINGEApril 2024July 2025Allow1410NoNo
18631675RAPAMYCIN RESISTANT CELLSApril 2024December 2025Allow2001YesNo
18623677COMPOSITIONS OF FUNCTIONAL MITOCHONDRIA AND USES THEREOFApril 2024March 2026Abandon2430YesNo
18622113ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOFMarch 2024July 2025Abandon1501NoNo
18612882ENGINEERED CLASS 2, TYPE V REPRESSOR SYSTEMSMarch 2024September 2025Allow1831NoNo
18589909UTERINE-DERIVED REGENERATIVE CELL COMPOSITIONS AND USES THEREOFFebruary 2024January 2025Allow1021YesNo
18589244NEURONAL REGENERATION PROMOTING CELLS (NRPCs) AND TREATING DAMAGED NERVE CELLSFebruary 2024March 2026Abandon2431NoNo
18584462PROGRAMMABLE NUCLEASES AND METHODS OF USEFebruary 2024December 2025Abandon2201NoNo
18442444Non-Human Animals Expressing Humanized CD3 ComplexFebruary 2024June 2025Allow1601YesNo
18437775METHODS AND COMPOSITIONS FOR THE PRODUCTION OF OLIGODENDROCYTE PROGENITOR CELLSFebruary 2024September 2024Allow710NoNo
18435757THREE-DIMENSIONAL MICROTISSUES WITH INTEGRATED MECHANICAL LOADINGFebruary 2024June 2025Allow1611YesNo
18434746EXPRESSION CASSETTE CONTAINING OVERLAPPING OPEN READING FRAMES AND APPLICATIONFebruary 2024July 2025Allow1721YesNo
18433553MEDIA FOR CULTURING NAIVE HUMAN PLURIPOTENT STEM CELLSFebruary 2024March 2026Allow2521NoNo
18294032METHOD FOR OBTAINING A PLATELET DERIVED SECRETOME AND USES THEREOFJanuary 2024February 2026Allow2411YesNo
18418864THERAPEUTIC AGENTSJanuary 2024August 2025Allow1910NoNo
18413219MOUSE HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENEJanuary 2024April 2025Allow1511YesNo
18410576ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATIONJanuary 2024September 2024Allow810NoNo
18409695KIT FOR BREEDING A TGEV INFECTION RESISTANT PIG AND USE THEREOFJanuary 2024January 2025Allow1221YesNo
18395362SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAMEDecember 2023May 2024Allow510NoNo
18541448GENERATION OF ALVEOLAR EPITHELIAL TYPE 1 (AT1) CELLSDecember 2023February 2025Allow1421YesNo
18539589METHOD FOR PRODUCING DOPAMINERGIC NEURON PROGENITOR CELLDecember 2023August 2025Allow2020YesNo
18538999VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICSDecember 2023December 2025Abandon2410NoNo
18526758METHODS FOR TARGETED INSERTION OF DNA IN GENESDecember 2023December 2024Allow1310YesNo
18526745METHODS FOR TARGETED INSERTION OF DNA IN GENESDecember 2023April 2024Allow410YesNo
18524967GENE THERAPY FOR AADC DEFICIENCYNovember 2023June 2025Allow1910NoNo
18518212ABCA4 TRANS-SPLICING MOLECULESNovember 2023June 2025Allow1932YesNo
18515879METHOD FOR REDUCING IMMUNOGENICITY OF RNANovember 2023July 2025Allow2010NoNo
18562767AGENT FOR IMPROVING CANCER CACHEXIA AND METHOD FOR IMPROVING CANCER CACHEXIANovember 2023December 2024Abandon1310YesNo
18512843EFFICIENT AND NON-GENETICALLY MODIFIED IPSC-INDUCED, INDUSTRIALIZED SINGLE CLONE SELECTION PLATFORM, AND USENovember 2023October 2025Allow2331YesNo
18503557GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHYNovember 2023July 2025Abandon2021NoNo
18490841METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEMOctober 2023February 2026Allow2820NoNo
18381652VASCULARIZED CARDIAC ORGANOID WITH A CHAMBER STRUCTURE AND ITS PREPARATION METHODOctober 2023September 2024Allow1110YesNo
18381660VASCULARIZED ISLET AND PREPARATION METHOD THEREOFOctober 2023February 2025Abandon1620NoNo
18487457METHOD OF PRODUCING A MESODERMAL-LINEAGE PRIMITIVE STREAK CELLOctober 2023March 2026Allow2900NoNo
18486682Recombinant Adeno-Associated Vectors For Targeted TreatmentOctober 2023August 2025Abandon2210NoNo
18484279VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCEOctober 2023August 2025Allow2221YesNo
18476774SCAFFOLDS TO TREAT SOLID TUMOR CELLS AND ESCAPE VARIANTSSeptember 2023December 2025Abandon2711NoNo
18474821CARDIOGENIC MESODERM FORMATION REGULATORSSeptember 2023March 2026Abandon2920NoNo
18472441THERAPEUTIC AGENTSSeptember 2023December 2025Allow2711NoNo
18371636FORMATION OF ARRAYS OF PLANAR INTESTINAL CRYPTS POSSESSING A STEM/PROLIFERATIVE CELL COMPARTMENT AND DIFFERENTIATED CELL ZONESeptember 2023September 2024Allow1120YesNo
18371839FUNCTIONAL FELINE PANCREATIC CELLS FROM ADIPOSE TISSUESeptember 2023December 2025Allow2611YesNo
18472072UNIVERSAL DONOR CELLS AND RELATED METHODSSeptember 2023November 2025Allow2610NoNo
18468820CRYOPROTECTIVE COMPOSITIONS AND USES THEREOFSeptember 2023May 2025Abandon2010NoNo
18468594OPTIMIZED EXPRESSION CASSETTES FOR GENE THERAPYSeptember 2023July 2024Allow1021YesNo
18453897RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLSAugust 2023February 2026Allow3011NoNo
18278100METHODS FOR CULTURING AND DIFFERENTIATING PLURIPOTENT CELLS INTO PROGENITOR OR MATURE MUSCLE CELLS AND COMPOSITION COMPRISING SAID CELLSAugust 2023July 2025Allow2321YesNo
18449429ANTI-CANCER-ASSOCIATED NON-TUMOR CELL AGENT COMPRISING VIRUSAugust 2023August 2025Abandon2420NoNo
18448674Methods and Culture Substrates for Controlled Induction of Biomimetic Neural Tissues Comprising Singular Rosette StructuresAugust 2023September 2025Allow2510YesNo
18447346AQUACULTURED CRUSTACEAN AND METHOD OF PRODUCING SAMEAugust 2023February 2026Allow3020YesNo
18231518SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLSAugust 2023February 2025Allow1921YesNo
18446243GENE THERAPY FOR TREATING HEMOPHILIA AAugust 2023October 2025Abandon2611NoNo
18363453CNS GENE DELIVERY USING PERIPHERAL ADMINISTRATION OF AAV VECTORSAugust 2023March 2025Allow1910YesNo
18226877METHODS OF GENERATING A SYNTHETIC EMBRYOJuly 2023February 2024Allow610NoNo
18356029RECOMBINOGENIC NUCLEIC ACID STRANDS IN SITUJuly 2023January 2024Allow610NoNo
18223865COHESIVE THIN LIQUIDS TO PROMOTE SAFE SWALLOWING IN DYSPHAGIC PATIENTSJuly 2023February 2025Allow1920NoNo
18223733EXTENSIONAL VISCOSITY TO PROMOTE SAFE SWALLOWING OF FOOD BOLUSESJuly 2023February 2025Allow1920NoNo
18223338MODIFIED NK-92 haNK003 CELLS FOR THE CLINICJuly 2023August 2025Allow2520YesNo
18271677SIMULATION METHOD FOR CHRONIC ATROPHIC GASTRITIS (CAG) LESION AND IDENTIFICATION METHOD FOR MOUSE MODELINGJuly 2023May 2025Abandon2220NoNo
18347487CHIMERIC ANTIGEN RECEPTOR COMPRISING BCMA NANOBODY LINKED TO A CHIMERIC INTRACELLULAR SIGNALING DOMAINJuly 2023August 2024Allow1312YesNo
18260247Inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cellsJuly 2023November 2025Allow2900YesNo
18259828TRANSGENIC CORYJune 2023November 2025Allow2820YesNo
18340537COMPOSITIONS AND METHODS FOR ORGANOID GENERATION AND DISEASE MODELINGJune 2023November 2025Abandon2911NoNo
18337454TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENTJune 2023February 2024Allow810YesNo
18210821DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLSJune 2023May 2025Abandon2310NoNo
18335959HUMAN LIVER CHIMERIC NON-HUMAN ANIMAL WITH DEFICIENT P450 OXIDOREDUCTASE AND METHODS OF USING SAMEJune 2023August 2025Abandon2611NoNo
18335001METHODS AND COMPOSITIONS FOR MANUFACTURING EXTRACELLULAR MATRIXJune 2023April 2025Abandon2201NoNo
18332621METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2023April 2025Allow2210NoNo
18332620METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2023March 2025Allow2210NoNo
18328473SWITCH RECEPTORS USING IL-9 SIGNALING DOMAINSJune 2023September 2024Allow1621NoNo
18325321IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACHMay 2023January 2025Abandon2010NoNo
18322105ACCELERATION OF STEM CELL DIFFERENTIATIONMay 2023July 2025Abandon2610NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1632.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
163
Examiner Affirmed
104
(63.8%)
Examiner Reversed
59
(36.2%)
Reversal Percentile
67.8%
Higher than average

What This Means

With a 36.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1560
Allowed After Appeal Filing
307
(19.7%)
Not Allowed After Appeal Filing
1253
(80.3%)
Filing Benefit Percentile
6.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1632 - Prosecution Statistics Summary

Executive Summary

Art Unit 1632 is part of Group 1630 in Technology Center 1600. This art unit has examined 11,316 patent applications in our dataset, with an overall allowance rate of 46.1%. Applications typically reach final disposition in approximately 39 months.

Comparative Analysis

Art Unit 1632's allowance rate of 46.1% places it in the 5% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1632 receive an average of 2.42 office actions before reaching final disposition (in the 84% percentile). The median prosecution time is 39 months (in the 15% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.